 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 30mg compared to PRO-ACT matched placebo over long-term follow-up...

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene ) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Inc. (NASDAQ:CLNN  Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 410,400 shares, a decline of...

Short Interest in Clene Inc. (NASDAQ:CLNN) Declines By 28.4%

SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to ...

Clene to Present at Upcoming September Conferences

HC Wainwright reissued their buy rating on shares of Clene (NASDAQ:CLNN Free Report) in a research report sent to investors on Tuesday , Benzinga reports. They currently have a $7.00 price objective on the stock. CLNN has been the topic of a number of other research reports. Cantor Fitzgerald ...

Clene (NASDAQ:CLNN) Receives "Buy" Rating from HC Wainwright

Shares of Clene Inc. (NASDAQ:CLNN Get Free Report) have been given an average recommendation of Moderate Buy by the seven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the ...

Clene Inc. (NASDAQ:CLNN) Receives Consensus Rating of "Moderate Buy" from Analysts

19.3 month significant survival difference for CNM-Au8 treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (...

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Clene (CLNN Research Report) today and set a price target of $7.00. The compa... H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Clene (CLNN  Research Rep...

H.C. Wainwright Keeps Their Buy Rating on Clene (CLNN)

Clene Inc. (NASDAQ:CLNN  Free Report)  Research analysts at Cantor Fitzgerald reduced their FY2023 EPS estimates for shares of Clene in a report issued on Thursday, August 17th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($0.65) per share ...

FY2023 Earnings Estimate for Clene Inc. (NASDAQ:CLNN) Issued By Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Clene (NASDAQ:CLNN  Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has...

Clene (NASDAQ:CLNN) Earns Overweight Rating from Cantor Fitzgerald

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Watchers	2,691
52-Wk Low	$0.414
52-Wk High	$2.03

Market Cap	$38.3M
Volume (M)	243,486.00
52-Wk High	$2.03
52-Wk Low	$0.414

CLNN Clene Inc

About

Feed

News

Sentiment

Earnings

Fundamentals